The Role of a Single Dose of Pneumo-23 Vaccine in Preventing Recurrent Respiratory Tract Infection in Patients of Tertiary Public Infectious Diseases/ Immunodeficiencies Ambulatory

Fourteen subjects from the infectious diseases and immunodeficiencies ambulatory of a public tertiary hospital, São Paulo state, Brazil, who were up to 10 years of age, had received pneumococcal conjugated vaccine 10 (PCV-10), and were unable to develop an adequate response (G1); and >10 years of age that had not received PCV-10 (G2). For G1, blood samples were collected immediately prior to vaccination, and about 30-60 d post vaccination for the whole group. A specific IgG concentration ≥1.3 g/mL, at least in 60% of serotypes was considered a protective response. Clinical and serological response to PPV23 was assessed at approximately 1, 3, 6 months and 1 year after immunization.
Author(s): Luiz Euribel Prestes Carneiro

Abstract | PDF

Share This Article